Projects per year
Project Details
Description
This clinical trial describes the use of FGN-1, the sulfone metabolite of the non-steroidal anti-inflammatory drug sulindac in a randomized double-blind, placebo-controlled, multicenter, 12 month study of men with recurrent prostate cancer after radical prostatectomy. FGN-1 lacks cyclo-oxygenase inhibitory activity and presumably the gastrointestinal and renal side effects of sulindac.
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/98 → 9/30/99 |
Funding
- National Center for Research Resources
ASJC Scopus Subject Areas
- Cancer Research
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Finished
-
GENERAL CLINICAL RESEARCH CENTER
Tapley, D. (PI), Morris, T. (PI), Colten, H. (PI) & Al-Awqati, Q. (CoPI)
National Center for Research Resources
12/1/84 → 9/29/06
Project: Research project